FULC

Fulcrum Therapeutics Inc

FULC, USA

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

https://www.fulcrumtx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FULC
stock
FULC

Fulcrum Therapeutics(FULC.US) 10% Shareholder Sells US$58.38 Million in Common Stock 富途牛牛

Read more →
FULC
stock
FULC

$FULC stock is down 8% today. Here's what we see in our data. Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$14.5556

Analyst Picks

Strong Buy

2

Buy

1

Hold

3

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.07

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-9.88 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.12 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.08

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 102.87% of the total shares of Fulcrum Therapeutics Inc

1.

RA Capital Management, LLC

(18.9107%)

since

2025/06/30

2.

TCG Crossover Management, LLC

(9.7058%)

since

2025/06/30

3.

Suvretta Capital Management, LLC

(9.3968%)

since

2025/06/30

4.

Adage Capital Partners Gp LLC

(8.4838%)

since

2025/06/30

5.

BlackRock Inc

(8.0956%)

since

2025/06/30

6.

Nantahala Capital Management, LLC

(7.9278%)

since

2025/06/30

7.

Vanguard Group Inc

(5.8169%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(3.3501%)

since

2025/07/31

9.

Dimensional Fund Advisors, Inc.

(2.5376%)

since

2025/06/30

10.

Balyasny Asset Management LLC

(2.474%)

since

2025/06/30

11.

iShares Russell 2000 ETF

(2.4308%)

since

2025/08/31

12.

State Street Corp

(2.2524%)

since

2025/06/30

13.

Geode Capital Management, LLC

(2.2058%)

since

2025/06/30

14.

D. E. Shaw & Co LP

(2.1754%)

since

2025/06/30

15.

Goldman Sachs Group Inc

(2.1141%)

since

2025/06/30

16.

Woodline Partners LP

(1.6594%)

since

2025/06/30

17.

Northern Trust Corp

(1.1306%)

since

2025/06/30

18.

Fidelity Small Cap Index

(0.9931%)

since

2025/06/30

19.

Point72 Asset Management, L.P.

(0.9211%)

since

2025/06/30

20.

Amvescap Plc.

(0.8695%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8497%)

since

2025/07/31

22.

Exome Asset Management LLC

(0.8226%)

since

2025/06/30

23.

Ikarian Capital, LLC

(0.7922%)

since

2025/06/30

24.

iShares Russell 2000 Value ETF

(0.7891%)

since

2025/08/31

25.

Charles Schwab Investment Management Inc

(0.7169%)

since

2025/06/30

26.

Invesco Dorsey Wright SmallCap Momt ETF

(0.6649%)

since

2025/08/29

27.

Vanguard Russell 2000 ETF

(0.4704%)

since

2025/07/31

28.

Xtrackers S&P 500 2xLev Dly Swap ETF 1C

(0.4627%)

since

2025/07/31

29.

State St Russell Sm Cap® Indx SL Cl I

(0.4439%)

since

2025/08/31

30.

Fidelity Extended Market Index

(0.4336%)

since

2025/07/31

31.

DFA US Small Cap I

(0.4161%)

since

2025/07/31

32.

DFA US Micro Cap I

(0.3766%)

since

2025/07/31

33.

Schwab US Small-Cap ETFâ„¢

(0.3729%)

since

2025/08/30

34.

Dimensional US Small Cap ETF

(0.2801%)

since

2025/08/29

35.

Dimensional US Targeted Value ETF

(0.2642%)

since

2025/08/29

36.

abrdn Life Sciences Investors

(0.2551%)

since

2025/08/31

37.

Northern Small Cap Value

(0.2529%)

since

2025/06/30

38.

NT Quality Small Cap Value

(0.2529%)

since

2025/06/30

39.

Schwab Small Cap Index

(0.2513%)

since

2025/07/31

40.

Avantis US Small Cap Equity ETF

(0.247%)

since

2025/08/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.31

Latest Release

Date

2025-09-30

EPS Actual

-0.31

EPS Estimate

-0.29

EPS Difference

-0.02

Surprise Percent

-6.8966%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.